Adit A. Ginde

Adit A. Ginde

Auto-generated profile, based on publicly available information

Adit A. Ginde

Department of Emergency Medicine, University of Colorado School of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
THThomas L. Holland
Thomas L. Holland
AGAdit A. Ginde
Adit A. Ginde
RPRoger Paredes
Roger Paredes
TMThomas A. Murray
Thomas A. Murray
NENicole Engen
Nicole Engen
JLJens D. Lundgren
Jens D. Lundgren

10 October 2014 in Academic Emergency Medicine
Verified
Journal Article
Open access
PDF file
PPPaul Pukurdpol
Paul Pukurdpol
JWJennifer L Wiler
Jennifer L Wiler
RHRenee Y Hsia
Renee Y Hsia
AGAdit A Ginde
Adit A Ginde
Objectives: Policymakers have increasingly focused on emergency department (ED) utilization for primary care–treatable conditions as a potentially avoidable source of rising health care costs. The objective was to determine the association of health insurance type and arrival time, as indicators of limited availability of primary care, with primary care–treatable classification of ED visits.Methods: This was a retrospective analysis of a nationally representative sample of 241,167 ED visits from the 1997 to 2009 National Hospital Ambulatory Medical Care Surveys (NHAMCS). Probabilities of ED visits being primary care–treatable were categorized based on the primary International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) code. The association of health insurance type and arrival time was determined with the average probability of the primary diagnosis being primary care–treatable using multivariable linear regression.Results: Compared to privately insured visits, Medicaid visits had a 1.7% (95% confidence interval [CI] = 1.2% to 2.2%) and uninsured visits a 2.4% (95% CI = 1.9% to 3.0%) higher probability of primary care–treatable classification, while Medicare visits had a 1.4% (95% CI = 0.7% to 2.0%) lower probability during the overall study period. Compared to business hours, weekend visits had a 1.5% (95% CI = 1.0% to 2.0%) higher probability of being primary care–treatable during the overall study period. From 1997 to 2009, the overall adjusted probability of ED visits being primary care–treatable increased by 0.19% (95% CI = 0.10 to 0.28) per year. This probability increased at a rate of 0.52% per year for Medicare visits (95% CI = 0.38% to 0.65%), more than double that of Medicaid visits (0.25% per year, 95% CI = 0.13% to 0.37%). By contrast, there was no significant change from 1997 to 2009 in the average probability of ED visits being primary care–treatable by privately insured (0.05% per year, 95% CI = –0.07 to 0.16) or uninsured (0.00% per year, 95% CI = –0.12 to 0.13) individuals.Conclusions: These findings add to prior work that implicates insurance type and arrival time in the variation of primary care–treatable ED visits. Although primary care–treatable classification of ED visits was most associated with uninsured or Medicaid visits, this classification increased most rapidly among Medicare visits during the study period.

6 August 2024 in JAMA
Verified
Journal Article
Open access
PDF file
LWLorraine B. Ware
Lorraine B. Ware
DFD. Clark Files
D. Clark Files
AFAlpha Alsbury Fowler
Alpha Alsbury Fowler
MAMichael S. Aboodi
Michael S. Aboodi
NANeil R. Aggarwal
Neil R. Aggarwal
ENEarly Treatment Of Acute Lung Injury Clinical Trials Network
Early Treatment Of Acute Lung Injury Clinical Trials Network
Importance: Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and other substrates.Objective: To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis compared with placebo.Design, Setting, and Participants: Phase 2b randomized, double-blind, clinical trial conducted from October 2021 to April 2023 with 90-day follow-up. Adults with sepsis and respiratory or circulatory organ dysfunction were enrolled in the emergency department or intensive care unit of 40 US academic hospitals within 36 hours of presentation.Intervention: Patients were randomized to 1 g of acetaminophen intravenously every 6 hours or placebo for 5 days.Main Outcome and Measures: The primary end point was days alive and free of organ support (mechanical ventilation, vasopressors, and kidney replacement therapy) to day 28. Treatment effect modification was evaluated for acetaminophen by prerandomization plasma cell-free hemoglobin level higher than 10 mg/dL.Results: Of 447 patients enrolled (mean age, 64 [SD, 15] years, 51% female, mean Sequential Organ Failure Assessment [SOFA] score, 5.4 [SD, 2.5]), 227 were randomized to acetaminophen and 220 to placebo. Acetaminophen was safe with no difference in liver enzymes, hypotension, or fluid balance between treatment arms. Days alive and free of organ support to day 28 were not meaningfully different for acetaminophen (20.2 days; 95% CI, 18.8 to 21.6) vs placebo (19.6 days; 95% CI, 18.2 to 21.0; P = .56; difference, 0.6; 95% CI, −1.4 to 2.6). Among 15 secondary outcomes, total, respiratory, and coagulation SOFA scores were significantly lower on days 2 through 4 in the acetaminophen arm as was the rate of development of acute respiratory distress syndrome within 7 days (2.2% vs 8.5% acetaminophen vs placebo; P = .01; difference, −6.3; 95% CI, −10.8 to −1.8). There was no significant interaction between cell-free hemoglobin levels and acetaminophen.Conclusions and Relevance: Intravenous acetaminophen was safe but did not significantly improve days alive and free of organ support in critically ill sepsis patients.Trial Registration: ClinicalTrials.gov Identifier: NCT04291508

17 February 2021 in JAMA
Verified
Journal Article
Open access
PDF file
DLDavid E. Leaf
David E. Leaf
AGAdit A. Ginde
Adit A. Ginde
Biological activity of vitamin D and its metabolites include, among other properties, potent antimicrobial and anti-inflammatory effects in vitro. In animal mod

10 October 2021 in Clinical Trials
Verified
Journal Article
Open access
PDF file
DMDaniel Murray
Daniel Murray
ABAbdel G. Babiker
Abdel G. Babiker
JBJason V. Baker
Jason V. Baker
CBChristina E Barkauskas
Christina E Barkauskas
SBSamuel M. Brown
Samuel M. Brown
JLJens Lundgren
Jens Lundgren
Background/aims: Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines public–private partnership initiated the Therapeutics for Inpatients with COVID-19. Therapeutics for Inpatients with COVID-19 is a multi-arm, multi-stage platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate antiviral therapeutic agents for adults hospitalized with COVID-19. Five agents have so far entered the protocol, with rapid answers already provided for three of these. Other agents are expected to enter the protocol throughout 2021. This protocol contains a number of key design and implementation features that, along with challenges faced by the protocol team, are presented and discussed. Methods: Three clinical trial networks, encompassing a global network of clinical sites, participated in the protocol development and implementation. Therapeutics for Inpatients with COVID-19 utilizes a multi-arm, multi-stage design with an agile and robust approach to futility and safety evaluation at 300 patients enrolled, with subsequent expansion to full sample size and an expanded target population if the agent shows an acceptable safety profile and evidence of efficacy. Rapid recruitment to multiple agents is enabled through the sharing of placebo, the confining of agent-specific information to protocol appendices, and modular consent forms. In collaboration with the Food and Drug Administration, a thorough safety data collection and Data and Safety Monitoring Board schedule was developed for the study of potential therapeutic agents with limited in-human data in hospitalized patients with COVID-19. Results: As of 8 August 2021, five agents have entered the Therapeutics for Inpatients with COVID-19 master protocol and a total of 1909 participants have been randomized to one of these agents or matching placebo. There were a number of challenges faced by the study team that needed to be overcome in order to successfully implement Therapeutics for Inpatients with COVID-19 across a global network of sites. These included ensuring drug supply and reliable recruitment allowing for changing infection rates across the global network of sites, the need to balance the collection of data and samples without overburdening clinical staff and obtaining regulatory approvals across a global network of sites. Conclusion: Through a robust multi-network partnership, the Therapeutics for Inpatients with COVID-19 protocol has been successfully used across a global network of sites for rapid generation of efficacy data on multiple novel antiviral agents. The protocol design and implementation features used in this protocol, and the approaches to address challenges, will have broader applicability. Mechanisms to facilitate improved communication and harmonization among country-specific regulatory bodies are required to achieve the full potential of this approach in dealing with a global outbreak.

20 May 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CGCarlos G Grijalva
Carlos G Grijalva
LFLeora R Feldstein
Leora R Feldstein
HTH Keipp Talbot
H Keipp Talbot
MAMichael Aboodi
Michael Aboodi
ABAdrienne H Baughman
Adrienne H Baughman
INInfluenza And Other Viruses In The Acutely Ill (Ivy) Network
Influenza And Other Viruses In The Acutely Ill (Ivy) Network
Influenza vaccine effectiveness (VE) against a spectrum of severe disease, including critical illness and death, remains poorly characterized. We conducted a test-negative study in an intensive care unit (ICU) network at 10 US hospitals to evaluate VE for preventing influenza-associated severe acute respiratory infection (SARI) during the 2019–2020 season, which was characterized by circulation of drifted A/H1N1 and B-lineage viruses. Cases were adults hospitalized in the ICU and a targeted number outside the ICU (to capture a spectrum of severity) with laboratory-confirmed, influenza-associated SARI. Test-negative controls were frequency-matched based on hospital, timing of admission, and care location (ICU vs non-ICU). Estimates were adjusted for age, comorbidities, and other confounders. Among 638 patients, the median (interquartile) age was 57 (44–68) years; 286 (44.8%) patients were treated in the ICU and 42 (6.6%) died during hospitalization. Forty-five percent of cases and 61% of controls were vaccinated, which resulted in an overall VE of 32% (95% CI: 2–53%), including 28% (−9% to 52%) against influenza A and 52% (13–74%) against influenza B. VE was higher in adults 18–49 years old (62%; 95% CI: 27–81%) than those aged 50–64 years (20%; −48% to 57%) and ≥65 years old (−3%; 95% CI: −97% to 46%) (P = .0789 for interaction). VE was significantly higher against influenza-associated death (80%; 95% CI: 4–96%) than nonfatal influenza illness. During a season with drifted viruses, vaccination reduced severe influenza-associated illness among adults by 32%. VE was high among young adults.